Daily Alpha · Reddit
· Post-Market Alpha · by Buzzberg Research
Reddit's highest-engagement cards were bearish on IREN, bullish on UUUU/UBER, short EXEL, and focused on Bessent's yen intervention; daily threads centered on oil-driven market risk.
Themes on this desk
Oil & geopolitics
Broad selloff on Iran escalation; oil above $96 and 10Y highest since 2023.
AI safety
Anthropic researcher resignation fuels existential risk discussion.
IREN funding
Hard pass on IREN due to capex gap and dilution.
Highest engagement
by score · day changeTreasury Secretary Bessent claims insider info to squeeze yen shorts
A Reddit post quotes Treasury Secretary Bessent saying he has inside info and is 'the house now' to yen short-sellers, suggesting he is using insider information to squeeze shorts and prevent yen carry trade unwinding. The post links this to potential tech stock impact if carry trade blows up.
I've got inside info. I'm the house now."
Government intervention in FX markets could distort risk pricing and increase volatility in tech equities.
Watch Monitor yen movements and any official statements from Treasury or BOJ.
Source →Full-port UUUU bet on uranium and rare earth supply chain
A user is going all-in on UUUU, citing control of the only US uranium mill with Pentagon-backed rare earth processing, Russian uranium import ban through 2028, and Section 232 proclamation. Expects 300-400% gain by 1H2027, possibly 8x on geopolitical events.
I am full-porting and not considering selling until 300-400% gain, hopefully realized within the first half of 2027, but I
UUUU could benefit from US strategic resource independence and geopolitical tensions.
Watch Watch for policy changes, rare earth production milestones, and uranium price movements.
Source →EXEL short thesis on generic competition
A user presents a short thesis on EXEL, claiming FDA approval of Handa's generic cabozantinib threatens its main revenue driver. Exelixis withdrew its lawsuit and its citizen petition failed, but the news is mostly in Taiwanese sources and not repriced by US markets.
I think Wall St has genuinely not yet put two and two together**, that this company's main source of revenue
Generic entry could significantly impact EXEL's ~$2B annual Cabometyx revenue.
Watch Watch for generic launch timing, EXEL's response, and market repricing.
Source →Most argued
by comments per upvoteUBER long thesis after robotaxi selloff
A user sold META and is now bullish on UBER, arguing the robotaxi-driven selloff is overdone. They cite UBER's profitability, global scale via Delivery Hero (99 countries), and regulatory/technical hurdles for robotaxis. Target price $130.
As of now I did some DCFs calculations plus some technical analysis which led to my target share price of
UBER may be undervalued if robotaxi disruption is slower than feared.
Watch Watch for robotaxi regulatory approvals, UBER earnings, and delivery margin trends.
Source →